A5013421605- Lung Cancer Research Studies
- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Radiomics and Machine Learning in Medical Imaging
- Cancer Genomics and Diagnostics
- Peptidase Inhibition and Analysis
- COVID-19 Clinical Research Studies
- RNA modifications and cancer
- Ferroptosis and cancer prognosis
- Lung Cancer Diagnosis and Treatment
- Inflammatory Biomarkers in Disease Prognosis
- Neuroendocrine Tumor Research Advances
- Liver physiology and pathology
- Chemokine receptors and signaling
- Sepsis Diagnosis and Treatment
- COVID-19 diagnosis using AI
- SARS-CoV-2 and COVID-19 Research
- Immune Cell Function and Interaction
- Cancer Mechanisms and Therapy
- Polyomavirus and related diseases
- Biomedical Ethics and Regulation
- HER2/EGFR in Cancer Research
- Artificial Intelligence in Healthcare and Education
- Multiple and Secondary Primary Cancers
- PI3K/AKT/mTOR signaling in cancer
Hospital Del Mar
2017-2025
Hospital del Mar Research Institute
2017-2023
Municipal Institute for Medical Research
2017-2023
Centro de Investigación Biomédica en Red de Cáncer
2020-2023
Universitat de Barcelona
2017-2019
Hospital Universitari Germans Trias i Pujol
2015-2016
Institut Català d'Oncologia
2015-2016
Badalona Serveis Assistencials
2016
Background. Immunotherapy has shown efficacy in small cell lung cancer (SCLC), but only a subset of patients benefits. Surrogate biomarkers are urgently needed. Our aim was to evaluate serum Th1, Th2, and proinflammatory cytokines two cohorts SCLC before during treatment with chemotherapy or without ipilimumab correlate them survival.Patients methods. Two were studied: treated (n = 47), plus 37). Baseline, on-treatment after-treatment samples evaluated for the presence IL-1beta, IL-2, IL-4,...
Introduction Immunotherapy is firmly established as a treatment regimen in various solid tumors, driven by its exceptional benefits selected group of patients. Despite widespread adoption immune checkpoint blockade (ICB) across diverse the quest for clinically informative biomarker long-term benefit remains unmet.
Small-cell lung cancer (SCLC) is often associated with paraneoplastic syndromes. To assess the role of anti-neuronal autoantibodies (NAAs) as biomarkers treatment outcome, we assessed NAAs in serial samples from SCLC patients treated chemoimmunotherapy compared to chemotherapy alone. We evaluated 2 cohorts: cohort 1 (C1), 47 received standard platinum/etoposide, and (C2), 38 ipilimumab, carboplatin etoposide. Serum at baseline subsequent time points were analyzed for presence NAAs. detected...
Abstract T-DM1 is an antibody drug conjugate that combines trastuzumab with emtansine via a stable thioether linker. In two phase III clinical trials, EMILIA and TH3RESA, was shown to be effective in HER2-positive metastatic breast cancer patients who had progressed taxanes trastuzumab. We have performed real-world study complement the findings of trials. From 2012 2016, 15 prior treatment received at our center. retrospectively analyzed outcomes these compared those Progression-free...
Abstract Tools for the evaluation of COVID-19 severity would help clinicians with triage decisions, especially decision whether to admit ICU. The aim this study was evaluate SeptiCyte RAPID, a host immune response assay (Immunexpress, Seattle USA) as triaging tool patients requiring hospitalization and potentially ICU care. RAPID employs gene expression signature consisting ratio levels two related mRNAs, PLA2G7 PLAC8, measured from whole blood samples. Blood samples 146 adult SARS-CoV-2 (+)...
Next-generation sequencing (NGS) is currently widely used for biomarker studies and molecular profiling to identify concurrent alterations that can lead the better characterization of a tumor's landscape. However, further evaluation technical aspects related detection gene rearrangements copy number warranted. There were 12 ALK rearrangement-positive tumor specimens from patients with non-small cell lung cancer (NSCLC) previously detected via fluorescence in situ hybridization (FISH),...
Abstract The rapid spread of the severe acute respiratory syndrome coronavirus 2 led to a global overextension healthcare. Both Chest X-rays (CXR) and blood test have been demonstrated predictive value on Coronavirus Disease 2019 (COVID-19) diagnosis different prevalence scenarios. With objective improving accelerating COVID-19, multi modal prediction algorithm (MultiCOVID) based CXR was developed, discriminate between Heart Failure Non-COVID Pneumonia healthy (Control) patients. This...
Hyperprogressive disease (HPD) as a consequence of immune checkpoint inhibitors in NSCLC has been reported multiple studies. However, inconsistent results incidence and survival outcomes within studies, together with different assessment methods, have led to increasing controversy regarding the concept HPD.Consecutive patients treated nivolumab (N = 42) or docetaxel 37) were evaluated. HPD was quantified by applying three methods (tumor growth rate [TGR], tumor kinetics [TGK], Response...
Cancer patients with severe renal dysfunction represent a challenge for the physician. This is first case report on use of denosumab in dialysis patient bone metastases. We present clinical 45-year-old woman who had hepatorenal polycystic disease, diagnosed during childhood, and stage IV chronic kidney failure at time breast cancer diagnosis. Three years after surgery plus adjuvant hormonal therapy she suffered further worsening function, requiring dialysis, very advanced metastasis hip...
e22139 Background: During the last years, new predictive and less frequent biomarkers have emerged in NSCLC, such as ROS1 translocation (ROS1t), HER2 mutations (HER2m) BRAF (BRAFm). We analyze retrospectively frequency, clinical tumor characteristics of NSCLC p TN( EGFR, KRAS ALK wild-type). Methods: The study included data from all consecutive non-squamous non-smokers squamous TN advanced diagnosed at our hospital December 2008 to July 2014. Results: 101 were included. table below...